Humacyte, Inc. Files 8-K, Formerly Alpha Healthcare
Ticker: HUMAW · Form: 8-K · Filed: Oct 28, 2024 · CIK: 1818382
| Field | Detail |
|---|---|
| Company | Humacyte, Inc. (HUMAW) |
| Form Type | 8-K |
| Filed Date | Oct 28, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, company-update
TL;DR
Humacyte (formerly Alpha Healthcare) filed an 8-K on 10/28/24. Nothing major, just corporate housekeeping.
AI Summary
Humacyte, Inc. filed an 8-K on October 28, 2024, reporting other events and financial statements. The company was formerly known as Alpha Healthcare Acquisition Corp. before changing its name on July 16, 2020.
Why It Matters
This filing provides an update on Humacyte's corporate status and financial reporting, which is important for investors to track the company's ongoing operations and any material changes.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for other events and financial statements, with no immediate indication of significant new risks.
Key Players & Entities
- Humacyte, Inc. (company) — Registrant
- Alpha Healthcare Acquisition Corp. (company) — Former company name
- October 28, 2024 (date) — Date of report
- July 16, 2020 (date) — Date of name change
FAQ
What is the primary purpose of this 8-K filing for Humacyte, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of October 28, 2024.
What was Humacyte, Inc.'s former name?
Humacyte, Inc.'s former name was Alpha Healthcare Acquisition Corp.
When did Humacyte, Inc. change its name from Alpha Healthcare Acquisition Corp.?
The name change from Alpha Healthcare Acquisition Corp. to Humacyte, Inc. occurred on July 16, 2020.
What is the principal executive office address for Humacyte, Inc.?
The principal executive offices of Humacyte, Inc. are located at 2525 East North Carolina Highway 54, Durham, NC 27713.
What is the SIC code for Humacyte, Inc.?
The Standard Industrial Classification (SIC) code for Humacyte, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 499 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-10-28 16:07:53
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share HUMA The Nasdaq Stock Market
- $11.50 — of Common Stock at an exercise price of $11.50 HUMAW The Nasdaq Stock Market LLC Ind
Filing Documents
- huma-20241028.htm (8-K) — 30KB
- huma-20241028xexx991.htm (EX-99.1) — 17KB
- image_0a.jpg (GRAPHIC) — 21KB
- 0001818382-24-000192.txt ( ) — 246KB
- huma-20241028.xsd (EX-101.SCH) — 2KB
- huma-20241028_def.xml (EX-101.DEF) — 16KB
- huma-20241028_lab.xml (EX-101.LAB) — 27KB
- huma-20241028_pre.xml (EX-101.PRE) — 16KB
- huma-20241028_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On October 28, 2024, Humacyte, Inc. (the "Company") issued a press release announcing the presentation of positive results from its Phase 3 clinical trial (V007) of the acellular tissue engineered vessel (ATEV) in arteriovenous access for patients with end-stage renal disease at the American Society of Nephrology's Kidney Week 2024. A copy of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press release, dated October 28 , 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HUMACYTE, INC. Date: October 28, 2024 By: /s/ Dale A. Sander Name: Dale A. Sander Title: Chief Financial Officer, Chief Corporate Development Officer and Treasurer 2